Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery Disease
- 1 January 2003
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs & Aging
- Vol. 20 (8), 585-595
- https://doi.org/10.2165/00002512-200320080-00004
Abstract
Coronary artery disease (CAD) is prevalent in the elderly and often leads to disability. Consequently, strategies for optimising the prevention and treatment of CAD in the elderly are important from both the individual and societal perspectives. Although it is common knowledge that the elderly are heavy consumers of drugs, there is evidence to show that there is under-prescribing of evidence-based medical therapies in the home-dwelling elderly coronary patient and there may be overuse of some non-evidence-based (antioxidants) and purely symptomatic treatments. In particular, aspirin (acetylsalicylic acid), beta-adrenoceptor antagonists, ACE inhibitors and HMG-CoA reductase inhibitors are under-utilised. Although the evidence base is largely drawn from trials including patients younger than 75 years, it is reasonable to assume that the data applies to patients aged over 75 years and that better use of evidence-based medicines would provide benefits to the home-dwelling aged patient. Evidence from the few multifactorial studies available suggest possible benefits including reduction of cardiovascular events, less disability and better quality of life in old age. At the societal level, this would be reflected in fewer hospitalisations and institutionalisations, which means decreased cost of elderly care.Keywords
This publication has 100 references indexed in Scilit:
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drugThe American Journal of Cardiology, 2002
- Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic?Heart, 2002
- Treatment of the Elderly Post‐Myocardial Infarction PatientThe American Journal of Geriatric Cardiology, 2001
- Bad for the Heart, Bad For the Mind?Science, 2001
- Statins and Blockers of the Renin-Angiotensin SystemHypertension, 1999
- Lifetime risk of developing coronary heart diseaseThe Lancet, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Aging, Natural Death, and the Compression of MorbidityNew England Journal of Medicine, 1980